Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01483599 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
A Phase 2 study, sponsored by Janssen.
- Completed
- Registry status
- Phase 2
- Development phase
- 293
- Enrollment target
NCT01483599 is a Phase 2 study that has completed, run by Janssen. The registered enrollment target is 293 participants.
The verdict
NCT01483599, a Phase 2 study, has completed, sponsored by Janssen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 293 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
Interventions
- DRUG CNTO 1959 (5 mg)
- DRUG CNTO 1959 (15 mg)
- DRUG CNTO 1959 (50 mg)
- DRUG CNTO 1959 (100 mg)
- DRUG CNTO 1959 (200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2011-11-10 |
| Est. Completion | 2013-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01483599
The ClinicalTrials.gov registry entry for NCT01483599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CNTO 1959 (5 mg) is the first listed.
NCT01483599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01483599 about?
NCT01483599 is a clinical study titled "A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis". The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
What is the current status of trial NCT01483599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2011-11-10. Estimated completion is 2013-08-05.
What interventions are being tested in trial NCT01483599?
The interventions under investigation include: CNTO 1959 (5 mg) (DRUG), CNTO 1959 (15 mg) (DRUG), CNTO 1959 (50 mg) (DRUG), CNTO 1959 (100 mg) (DRUG), CNTO 1959 (200 mg) (DRUG).
Who is sponsoring clinical trial NCT01483599?
This trial is sponsored by Janssen, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.